Ashish Kamat, MD, MBBS, FACS

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    BioClin Therapeutics
    Date added:
    Date updated:
    08/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Roviant
    Date added:
    Date updated:
    08/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Photocure
    Date added:
    Date updated:
    08/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Merck
    Date added:
    Date updated:
    08/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    FerGene
    Date added:
    Date updated:
    08/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Astra Zeneca
    Date added:
    Date updated:
    08/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Heat Biologics
    Date added:
    Date updated:
    08/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (General Urology)
    Ineligible company:
    Adolor
    Date added:
    Date updated:
    08/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Leadership Position (Specialty Not Specified)
    Ineligible company:
    IBCG
    Date added:
    Date updated:
    08/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Specialty Not Specified)
    Ineligible company:
    FKD
    Date added:
    Date updated:
    08/25/2023

Pages

Return to The Journal of Urology Vol. 210 (2023): November